Literature DB >> 22050417

Morphofunctional changes underlying intestinal dysmotility in diabetic RIP-I/hIFNβ transgenic mice.

Anna Domènech1, Gianandrea Pasquinelli, Roberto De Giorgio, Alessandra Gori, Fàtima Bosch, Martí Pumarola, Marcel Jiménez.   

Abstract

The pathogenetic mechanisms underlying gastrointestinal dysmotility in diabetic patients remain poorly understood, although enteric neuropathy, damage to interstitial cells of Cajal (ICC) and smooth muscle cell injury are believed to play a role. The aim of this study was to investigate the morphological and functional changes underlying intestinal dysmotility in RIP-I/hIFNβ transgenic mice treated with multiple very low doses of streptozotocin (20 mg/kg, i.p., 5 days). Compared with vehicle-treated mice, streptozotocin-treated animals developed type 1 diabetes mellitus, with sustained hyperglycaemia for 3.5 months, polyphagia, polydipsia and increased faecal output without changes in faecal water content (metabolic cages). Diabetic mice had a longer intestine, longer ileal villi and wider colonic crypts (conventional microscopy) and displayed faster gastric emptying and intestinal transit. Contractility studies showed selective impaired neurotransmission in the ileum and mid-colon of diabetic mice. Compared with controls, the ileal and colonic myenteric plexus of diabetic mice revealed ultrastructural features of neuronal degeneration and HuD immunohistochemistry on whole-mount preparations showed 15% reduction in neuronal numbers. However, no immunohistochemical changes in apoptosis-related markers were noted. Lower absolute numbers of neuronal nitric oxide synthase- and choline acetyltransferase-immunopositive neurons and enhanced vasoactive intestinal polypeptide and substance P immunopositivity were observed. Ultrastructural and immunohistochemical analyses did not reveal changes in the enteric glial or ICC networks. In conclusion, this model of diabetic enteropathy shows enhanced intestinal transit associated with intestinal remodelling, including neuroplastic changes, and overt myenteric neuropathy. Such abnormalities are likely to reflect neuroadaptive and neuropathological changes occurring in this diabetic model.
© 2011 The Authors. International Journal of Experimental Pathology © 2011 International Journal of Experimental Pathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22050417      PMCID: PMC3248076          DOI: 10.1111/j.1365-2613.2011.00789.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  41 in total

Review 1.  The journey to establish purinergic signalling in the gut.

Authors:  G Burnstock
Journal:  Neurogastroenterol Motil       Date:  2008-05       Impact factor: 3.598

2.  Purinergic and nitrergic junction potential in the human colon.

Authors:  Diana Gallego; Víctor Gil; Jordi Aleu; Mariona Aulí; Pere Clavé; Marcel Jiménez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-07-03       Impact factor: 4.052

3.  The spontaneously diabetic Torii rat with gastroenteropathy.

Authors:  Kotaro Yamada; Masaya Hosokawa; Shimpei Fujimoto; Kazuaki Nagashima; Kazuhito Fukuda; Hideya Fujiwara; Eiichi Ogawa; Yoshihito Fujita; Naoya Ueda; Futoshi Matsuyama; Yuichiro Yamada; Yutaka Seino; Nobuya Inagaki
Journal:  Diabetes Res Clin Pract       Date:  2006-09-07       Impact factor: 5.602

4.  GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway.

Authors:  Mallappa Anitha; Chetan Gondha; Roy Sutliff; Alexander Parsadanian; Simon Mwangi; Shanthi V Sitaraman; Shanthi Srinivasan
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

5.  Expression of IGF-I in pancreatic islets prevents lymphocytic infiltration and protects mice from type 1 diabetes.

Authors:  Alba Casellas; Ariana Salavert; Judith Agudo; Eduard Ayuso; Veronica Jimenez; Marta Moya; Sergio Muñoz; Sylvie Franckhauser; Fatima Bosch
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

6.  Reduced insulin and IGF-I signaling, not hyperglycemia, underlies the diabetes-associated depletion of interstitial cells of Cajal in the murine stomach.

Authors:  Viktor J Horváth; Harsha Vittal; Tamás Ordög
Journal:  Diabetes       Date:  2005-05       Impact factor: 9.461

7.  Vitamin E supplementation in rats with experimental diabetes mellitus: analysis of myosin-V and nNOS immunoreactive myenteric neurons from terminal ileum.

Authors:  Renata Virginia Fernandes Pereira; Marcílio Hubner de Miranda-Neto; Ivan Domicio da Silva Souza; Jacqueline Nelisis Zanoni
Journal:  J Mol Histol       Date:  2008-10-24       Impact factor: 2.611

8.  Disturbed gastrointestinal motility and decreased interstitial cells of Cajal in diabetic db/db mice.

Authors:  Takahiro Yamamoto; Kenji Watabe; Masanori Nakahara; Hideharu Ogiyama; Tatsuya Kiyohara; Shusaku Tsutsui; Shinji Tamura; Yasuhisa Shinomura; Norio Hayashi
Journal:  J Gastroenterol Hepatol       Date:  2008-03-13       Impact factor: 4.029

Review 9.  Interstitial cells of Cajal in diabetic gastroenteropathy.

Authors:  T Ordög
Journal:  Neurogastroenterol Motil       Date:  2008-01       Impact factor: 3.598

10.  Characterization of myenteric neuropathy in the jejunum of spontaneously diabetic BB-rats.

Authors:  M Zandecki; P Vanden Berghe; I Depoortere; K Geboes; T Peeters; J Janssens; J Tack
Journal:  Neurogastroenterol Motil       Date:  2008-02-25       Impact factor: 3.598

View more
  17 in total

Review 1.  Interstitial cells of Cajal: update on basic and clinical science.

Authors:  Jan D Huizinga; Ji-Hong Chen
Journal:  Curr Gastroenterol Rep       Date:  2014-01

Review 2.  Diabetes and the Small Intestine.

Authors:  Jonathan Gotfried; Stephen Priest; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

3.  Circulating IGF-I and IGFBP3 Levels Control Human Colonic Stem Cell Function and Are Disrupted in Diabetic Enteropathy.

Authors:  Francesca D'Addio; Stefano La Rosa; Anna Maestroni; Peter Jung; Elena Orsenigo; Moufida Ben Nasr; Sara Tezza; Roberto Bassi; Giovanna Finzi; Alessandro Marando; Andrea Vergani; Roberto Frego; Luca Albarello; Annapaola Andolfo; Roberta Manuguerra; Edi Viale; Carlo Staudacher; Domenico Corradi; Eduard Batlle; David Breault; Antonio Secchi; Franco Folli; Paolo Fiorina
Journal:  Cell Stem Cell       Date:  2015-10-01       Impact factor: 24.633

Review 4.  Diabetes Mellitus and the Colon.

Authors:  Marc S Piper; Richard J Saad
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

5.  Interleukin-6 (IL-6) mediated the increased contraction of distal colon in streptozotocin-induced diabetes in rats via IL-6 receptor pathway.

Authors:  Xin-Wen Chang; Ying Qin; Zhi Jin; Tao-Fang Xi; Xiao Yang; Ze-Hao Lu; Yu-Ping Tang; Wen-Ting Cai; Shao-Jun Chen; Dong-Ping Xie
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 6.  Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions.

Authors:  S S Yarandi; S Srinivasan
Journal:  Neurogastroenterol Motil       Date:  2014-03-24       Impact factor: 3.598

7.  Myosin Va but Not nNOSα is Significantly Reduced in Jejunal Musculomotor Nerve Terminals in Diabetes Mellitus.

Authors:  Arun Chaudhury; Marcilio Hubner De Miranda-Neto; Renata Virginia Fernandes Pereira; Jacqueline Nelisis Zanoni
Journal:  Front Med (Lausanne)       Date:  2014-06-20

Review 8.  Purinergic signalling and diabetes.

Authors:  Geoffrey Burnstock; Ivana Novak
Journal:  Purinergic Signal       Date:  2013-04-03       Impact factor: 3.765

9.  Enteric motor pattern generators involve both myogenic and neurogenic mechanisms in the human colon.

Authors:  Noemí Mañé; Míriam Martínez-Cutillas; Diana Gallego; Marcel Jimenez
Journal:  Front Physiol       Date:  2015-07-21       Impact factor: 4.566

10.  Hepatic insulin gene therapy prevents diabetic enteropathy in STZ-treated CD-1 mice.

Authors:  Shuo You; Mallappa Anitha; Sean Md deSouza; Dingwu Jia; Xianghua Lu; Miroslaw Kozlowski; Darin E Olson; Shanthi Srinivasan; Peter M Thulé
Journal:  Mol Ther Methods Clin Dev       Date:  2015-09-02       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.